tbuckley/cabot-search huggingface dataset:
Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.
Authors: Jing Huang, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Ji Feng Feng, Shu Zhang, Yi Ba, Ying Liu, Chunmei Bai, Yu-Xian Bai, Yong Tang, Yan Song, Jie He
Journal: Journal of Clinical Oncology (2019)

95 Background: The treatment option for ESCC patients (pts) progressing after chemotherapy is still uncertain. Anlotinib is a multi-target tyrosine kinase inhibitor involved in tumor angiogenesis and growth, such as vascular endothelia growth factor receptor (VEGFR) 2/3, etc. Methods: Eligible pts were advanced ESCC who had progressed after platinum or taxane containing chemotherapy. Between January 6, 2016 and May 22, 2018, a total of 165 pts from 13 centers in China were randomly assigned (in a 2:1 ratio) to anlotinib arm (n=110), and placebo arm (n=55). Pts were given anlotinib (12 mg/day) or placebo orally from day 1 to day 14 in a 21-day cycle until disease progression or had unacceptable toxic effects. The primary end point was progression-free survival (PFS). Results: Median PFS was 3.0 months with anlotinib and 1.4 months with placebo (HR 0.5, 95% CI, 0.3-0.7; P&lt;0.0001). Complete response occured in 2 pts with anlotinib and 0 pt with placebo. The objective response rates were 7% in the anlotinib group and 4% in the placebo group (P=0.498), and the disease control rates (DCR) were 64% and 18%, respectively (P&lt;0.0001). In anlotinib arm, median duration of response was 5.8 months (range, 3.1-19.7+). Grade 3/4 treatment-related adverse events (TRAE) were reported in 36.7% and 11.0% of the two group pts, and grade 5 TRAE were 2.8% and 0%, respectively. The most common grade 3/4 TRAE (&gt;5%) in anlotinib arm were hypertension (15.6%) and loss of appetite (5.5%). Median overall survival were similar between the groups (6.1 months vs 7.2 months; HR 1.2, 95%CI 0.8-1.8, P=0.4261). The ratio of pts received post study treatments was 41.2% (40/97) in anlotinib arm and 72.7% (40/55) in placebo arm (P=0.0002), including chemotherapy (23.7% vs 54.6%), PD-1 inhibitors (4.1% vs 11.0%), and Apatinib, a VEGFR inhibitor, (10.3% vs 20.0%), etc. Conclusions: In pretreated advanced ESCC pts, anlotinib significantly improved PFS and DCR compared with placebo, with a manageable safety profile. Clinical trial information: NCT02649361.
Abstract 16722: Comparison of Tricuspid Annular Plane Systolic Excursion to Fractional Area Change for Evaluation of Right Ventricular Systolic Function: Systematic Review and Meta-analysis
Authors: Justin Z Lee, See-Wei Low, Seongseok Yun, Parinita Dherange, Ankit A Desai, Elizabeth Juneman, Kwan S Lee, Prakash Suryanarayana
Journal: Circulation (2015)

Introduction: Right ventricular (RV) systolic function is prognostically important, but its assessment by echocardiography remains challenging. Tricuspid annular plane systolic excursion (TAPSE) and fractional area change (FAC) have been evaluated as echocardiographic indices for RV ejection fraction (RVEF), but their correlation with the gold-standard cardiac magnetic resonance imaging (CMRI) remains unclear. The aim of this meta-analysis is to pool and compare data from all studies that evaluated reliability of TAPSE and FAC in comparison to CMRI-derived RVEF. Hypothesis: We assessed the hypothesis that FAC is superior to TAPSE as an echocardiographic index for measurement of RV systolic function. Methods: A systematic literature search of 4493 potentially relevant citations from PubMed, and EMBASE databases yielded 25 eligible studies. The means of TAPSE and FAC, CMRI-derived RVEF, and correlation coefficients were pooled from each study for analysis. Results: A total of 25 studies were included in the final analysis, with a total of 1,858 patients who underwent 2D-echocardiography and cardiac MRI. FAC, compared to TAPSE, exhibited numerically superior correlation to CMRI RVEF (R2 = 0.63, and R2 = 0.15 respectively). Subgroup analysis revealed that FAC’s correlation was also numerically superior in patients with reduced right ventricular ejection fraction of less than 45% (R2 = 0.4 and R2 = 0.17, respectively). In patients with pulmonary hypertension (PH), TAPSE and FAC had mean correlation coefficients of 0.57±0.1 and 0.60±0.13, and were not statistically different (p=0.85). Conclusions: FAC is superior to TAPSE as an echocardiographic index for measurement of RV systolic function, even in patients with reduced right ventricular ejection fraction, but not in patients with PH. The adaptation to increased afterload of PH likely culminates in distinct and asymmetric patterns of RV dysfunction, which are not well assessed by FAC or TAPSE.
Abstract 20239: Increased Prevalence of Major Depressive Disorder in Patients Who Get Admitted With Acute Myocardial Infarction With Worse Outcomes
Authors: Zeeshan Mansuri, Muhammad H Gul, Divyank Patel, Jay Shah, Kinsuk Chauhan, Achint Patel
Journal: Circulation (2016)

Objective: To determine the trends and impact on outcomes of Acute Myocardial Infarction (AMI) in patients with pre- existing Major Depressive Disorder (MDD). Background: While post- AMI MDD has be...
Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase
Authors: Koji Sasaki, Hagop M. Kantarjian, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William G. Wierda, Naval G. Daver, Alessandra Ferrajoli, Koichi Takahashi, Guillermo Montalban-Bravo, Mary B. Rios, Sherry A. Pierce, Kenichi Sakurai, Elias J. Jabbour, Jorge E. Cortes
Journal: Blood (2018)
Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine
Authors: Jiawei Wang, Lian Li, Jiyuan Yang, Phillip M. Clair, Martha Glenn, Deborah M. Stephens, D. Christopher Radford, Ken M. Kosak, Michael W. Deininger, Paul J Shami, Jindřich Kopeček
Journal: Blood (2018)
Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis
Authors: Archana Asundi, Alina Beliavsky, Xing Jian Liu, Arash Akaberi, Guido Schwarzer, Zeno Bisoffi, Ana Requena-Méndez, Ian Shrier, Christina Greenaway
Journal: The Lancet Global Health (2019)

BackgroundGlobal migration from regions where strongyloidiasis and schistosomiasis are endemic to non-endemic countries has increased the potential individual and public health effect of these parasitic diseases. We aimed to estimate the prevalence of these infections among migrants to establish which groups are at highest risk and who could benefit from screening.MethodsWe did a systematic review and meta-analysis of strongyloidiasis and schistosomiasis prevalence among migrants born in endemic countries. Original studies that included data for the prevalence of Strongyloides or Schistosoma antibodies in serum or the prevalence of larvae or eggs in stool or urine samples among migrants originating from countries endemic for these parasites and arriving or living in host countries with low endemicity—specifically the USA, Canada, Australia, New Zealand, Israel, and 23 western European countries—were eligible for inclusion. Pooled estimates of the prevalence of strongyloidiasis and schistosomiasis by stool or urine microscopy for larvae or eggs or serum antibodies were calculated with a random-effects model. Heterogeneity was explored by stratification by age, region of origin, migrant class, period of study, and type of serological antigen used.Findings88 studies were included. Pooled strongyloidiasis seroprevalence was 12·2% (95% CI 9·0–15·9%; I2 96%) and stool-based prevalence was 1·8% (1·2–2·6%; 98%). Migrants from east Asia and the Pacific (17·3% [95% CI 4·1–37·0]), sub-Saharan Africa (14·6% [7·1–24·2]), and Latin America and the Caribbean (11·4% [7·8–15·7]) had the highest seroprevalence. Pooled schistosomiasis seroprevalence was 18·4% (95% CI 13·1–24·5; I2 97%) and stool-based prevalence was 0·9% (0·2–1·9; 99%). Sub-Saharan African migrants had the highest seroprevalence (24·1·% [95% CI 16·4–32·7]).InterpretationStrongyloidiasis affects migrants from all global regions, whereas schistosomiasis is focused in specific regions and most common among sub-Saharan African migrants. Serological prevalence estimates were several times higher than stool estimates for both parasites. These data can be used to inform screening decisions for migrants and support the use of serological screening, which is more sensitive and easier than stool testing.FundingNone.
Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group
Authors: Frauke Theis, Daniela Weber, Frank G. Rücker, Peter Paschka, Verena I. Gaidzik, Felicitas Thol, Michael Heuser, Walter Fiedler, Gerald Wulf, Michael Lübbert, Helmut R. Salih, Thomas Michael Schroeder, Katharina S. Götze, Hans Jürgen Salwender, Thomas Kindler, Heinz-August Horst, Mark Ringhoffer, Dominik Wolf‎, Jürgen Krauter, Richard F. Schlenk, Lars Bullinger, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2018)
Abstract 19230: Clinical Significance of Early Repolarization in Long QT Syndrome
Authors: Alan Sugrue, Ram K Rohatgi, J. Martijn Bos, Samuel Asirvatham, Peter A Noseworthy, Michael J Ackerman
Journal: Circulation (2017)

Introduction: Early repolarization (ER) is associated with an increased risk of arrhythmic events and sudden cardiac death. There is limited data examining the clinical significance of ER in LQTS. The aim of our study was to therefore determine the prevalence of ER within a large cohort of patients with long QT syndrome (LQTS) and examine its clinical significance in terms of predicting symptoms and risk of breakthrough cardiac events (BCE). Methods: ER was defined as an end-QRS notch or slur on the downslope of a prominent R-wave with a J point ≥ 0.1 mV in 2 or more contiguous leads of the 12-lead ECG, excluding leads V1 to V3, with a QRS duration < 120 ms. The patient’s ECG with the most manifest ER was used for analysis. Major ER was defined as ≥ 2-mm J-point elevation. A patient was considered symptomatic if they had a suspected LQTS-triggered cardiac event prior to diagnosis (fetal arrhythmia, arrhythmogenic syncope/seizure, or cardiac arrest). BCEs were defined as LQTS-attributable syncope/seizures,...
The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Authors: Arnon Nagler, Myriam Labopin, Gerard Socie, Anne Huynh, Maija Itälä-Remes, Eric Deconinck, Ibrahim Yakoub-Agha, Jean-Yves Cahn, Jean-Henri Bourhis, Hélène Labussière-Wallet, Sylvain Chantepie, Jordi Esteve, Mohamad Mohty
Journal: Blood (2018)
Anaphylaxis during oral food challenge: can we predict it?
Authors: Bruna Pultrini Aquilante, Mariana Barp Melnik, Laìs Ferreira Brum, Andrea Solferini Barros, Maira Mastrocola Leite, Lais Pereira Millan, Tatiana Paskin Martins, Cristiane N. Santos, Mayra de Barros Dorna, Antonio Carlos Pastorino, Ana Paula Moschione Castro
Journal: Journal of Allergy and Clinical Immunology (2019)
Nasal and skin microbiomes are associated with disease severity in paediatric atopic dermatitis
Authors: J.E.E. Totté, L.M. Pardo, K.B. Fieten, M.C. Vos, T.J. Broek, F.H.J. Schuren, S.G.M.A. Pasmans
Journal: British Journal of Dermatology (2019)

Alterations of the skin microbiome have been associated with atopic dermatitis (AD) and its severity. The nasal microbiome in relation to AD severity is less well studied. We aimed to characterize the nasal and skin microbiomes in children with AD in relation to disease severity. In addition, we explored the differences and correlations between the nasal and skin communities. We characterized the microbial composition of 90 nasal and 108 lesional skin samples cross‐sectionally from patients with AD, using 16S‐rRNA sequencing. In addition, a quantitative polymerase chain reaction was performed for Staphylococcus aureus and Staphylococcus epidermidis on the skin samples, and AD severity was estimated using the self‐administered Eczema Area and Severity Index. We found an association between the microbial composition and AD severity in both the nose and skin samples (R2 = 2·6%; P = 0·017 and R2 = 7·0%; P = 0·004), strongly driven by staphylococci. However, other species also contributed, such as Moraxella in the nose. Skin lesions were positive for S. aureus in 50% of the children, and the presence and the load of S. aureus were not associated with AD severity. Although the nose and skin harbour distinct microbial communities (n = 48 paired samples; P < 0·001), we found that correlations exist between species in the nose and (other) species on the skin. Our results indicate that both the nasal and the skin microbiomes are associated with AD severity in children and that, next to staphylococci, other species contribute to this association.
Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma
Authors: Sho Kashiwazaki, Satoshi Kamiko, Ryo Uozaki, Tomofumi Yamamoto, Daiju Ichikawa, Yutaka Hattori, Maiko Matsushita, Maki Hirao, Hisako Kunieda, Kohei Yamazaki
Journal: Blood (2018)
Peroxiredoxin II (PRDX2) Is a Novel Candidate Gene for Congenital Dyserythropoietic Anemia
Authors: Myesa Emberesh, Katie Giger Seu, Sana Emberesh, Lisa Trump, Mary Risinger, Wenying Zhang, Ammar Husami, Carolyn Lutzko, Vinod Gidvani-Diaz, Robert B. Lorsbach, Theodosia A. Kalfa
Journal: Blood (2018)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Authors: Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah-Eddin Al-Batran, Eric Van Cutsem, David H Ilson, Maria Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter C Enzinger, Vera Gorbounova, Zev A Wainberg, Susanna Hegewisch-Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A Shah, Alexander V. Luft, Nina A. Karaseva, Rubén Dario Kowalyszyn, Carlos Alberto Hernandez, Tibor Csoszi, Ferdinando De Vita, Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, Gyorgy Bodoky, Georgina Garnica Jaliffe, Svetlana Protsenko, Ayman Madi, Elzbieta Wojcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Johanna Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar García Alfonso, Radka Obermannova, Hélène Senellart, Russell Petty, Leslie Samuel, Peter Istvan Acs, Maen Abdelkarim Hussein, Marina N. Nechaeva, F.L.G. Erdkamp, Elizabeth Won, Johanna Chock Bendell, Javier Gallego Plazas, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean-Marc Phelip, Diego Lucas Kaen, James A. Jr Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Enrique Fein, Angel Gomez Villanueva, Mohamed Hebbar, Jana Prausova, Laura Visa Turmo, Joana Vidal Barrull, Mette Karen Nytoft Yilmaz, Alex Beny, H.M.W. Van Laarhoven, Brian Anthony DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses Sundar Raj, Francisco Javier Ramirez Godinez, Agnes Ruzsa, Hugo Ford, William E. Lawler, Nicolas Robert Maisey, Jiri Petera, Einat Shacham-Shmueli, Isabelle Sinapi, Kensei Yamaguchi, Hiroki Hara, Joseph Thaddeus Beck, Maria Błasińska-Morawiec, Ricardo Villalobos Valencia, Thierry Alcindor, Madhuri Bajaj, Scott Berry, Christina Maria Gomez, Daniel Dammrich, Ravindranath Patel, Julien Taieb, A.J. Ten Tije, Ronald L. Burkes, Fernando Cabanillas, Irfan Firdaus, Cynthia Coo Chua, Shuichi Hironaka, Ralf-Dieter Hofheinz, Howard J. Lim, Marianne Nordsmark, Bela Piko, Udit Verma, Jonathan Wadsley, Seigo Yukisawa, Francisco Gutiérrez Delgado, Crystal S. Denlinger, Raija Kallio, Joanna Pikiel, Joanna Wojcik-Tomaszewska, Christine Brezden-Masley, Raymond Woo-Jun Jang, Jana Pribylova, Daisuke Sakai, Maria Alejandra Bartoli, A. Cats, M.I. Grootscholten, Robert Andrew Dichmann, Hugo Hool, Walid Shaib, Akihito Tsuji, Marc Van den Eynde, Hector Velez-Cortez, Timothy R. Asmis
Journal: The Lancet Oncology (2019)
Quantitative MALDI Imaging of Spatial Distributions and Dynamic Changes of Tetrandrine in Multiple Organs of Rats
Authors: Weiwei Tang, Jun Chen, Jie Zhou, Junyue Ge, Ying Zhang, Ping Li, Bin Li
Journal: Theranostics (2019)

Detailed spatio-temporal information on drug distribution in organs is of paramount importance to assess drug clinically-relevant properties and potential side-effects.Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) as a label-free and sensitive imaging modality provides an additional means of accurately visualizing drug and its metabolites distributions in tissue sections.However, technical limitations, complex physiochemical environment of surface and low abundance of target drugs make quantitative MALDI imaging of drug and its metabolites quite challenging.Methods: In this study, an internal standard correction strategy was applied for quantitative MALDI imaging of tetrandrine in multiple organs of rats including lung, liver, kidney, spleen, and heart.The feasibility and reliability of the developed quantitative MSI method were validated by conventional liquid chromatography-tandem MS (LC-MS/MS) analysis, and the two methods showed a significant correlation. Results:The quantitative MALDI imaging method met the requirements of specificity, sensitivity and linearity.Tissue-specific spatio-temporal distribution patterns of tetrandrine in different organs were revealed after intravenous administration in the rat.Moreover, demethylated metabolite was detected in liver tissues. Conclusions:The current work illustrates that quantitative MALDI imaging provides an alternative means of accurately addressing the problem of drug and its metabolites distribution in tissues, complementary to traditional LC-MS/MS of tissue homogenates and whole-body autoradiography (WBA).Quantitative spatio-chemical information obtained here can improve our understanding of pharmacokinetics (PK), pharmacodynamics (PD), and potential transient toxicities of tetrandrine in organs, and possibly direct further optimization of drug properties to reduce drug-induced organ toxicity.
Abstract 18172: Global Pulmonary Vascular Remodeling in Heart Failure With Pulmonary Hypertension: A Comparison to Pulmonary Veno-occlusive Disease and Normal Controls
Authors: Ahmed U Fayyaz, William D Edwards, Joseph J Maleszewski, Ewa A Konik, Hilary M DuBrock, Sarah M Jenkins, Robert P Frantz, Margaret M Redfield
Journal: Circulation (2017)

Introduction: Most forms of Group 1 pulmonary hypertension (PH) have isolated pulmonary arteriopathy with sparing of pulmonary veins. Group 1’ PH (pulmonary veno-occlusive disease, PVOD) is charact...
Abstract 16734: Partial Inhibition of Fatty Acid Oxidation Improves Oxidative Metabolism and Right Ventricular Function in Pulmonary Arterial Hypertension Rats
Authors: Ali Ahmadi, Jennifer M Renaud, Julia Petryk, Tayebeh Hadizad, Terrence D Ruddy, Jason R Dyck, Rob S Beanlands, Robert A deKemp, Gary D Lopaschuk, Lisa M Mielniczuk
Journal: Circulation (2017)

Introduction: We hypothesized that metabolic modulation by inhibiting fatty acid oxidation improves right ventricular (RV) failure in rat models of pulmonary arterial hypertension (PAH). Methods: T...
Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab
Authors: Ralf C Bargou, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, Max S. Topp, Qui Tran, Xinke Zhang, Nicola Goekbuget
Journal: Blood (2018)
CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study
Authors: Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Rikio Suzuki, Yasuhiro Taniguchi, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Yasuhisa Yokoyama, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki
Journal: Blood (2018)
Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).
Authors: Benjamin A. Krantz, Erika Gedvilaite, Joanne F. Chou, Marinela Capanu, Daoqi You, Kenneth H. Yu, Anna M. Varghese, Christine A Iacobuzio-Donahue, David Paul Kelsen, Dana Tsui, Eileen Mary O'Reilly
Journal: Journal of Clinical Oncology (2019)

294 Background: Validated predictive and prognostic biomarkers are needed in PDAC. Such biomarkers could predict response and resistance early in treatment. As 95% of PDAC harbor KRAS mutations (mKRAS), plasma mKRAS has utility as a biomarker. We explored the prognostic value of mKRAS in a PDAC cohort at Memorial Sloan Kettering. Methods: 10 mL of whole blood was collected at diagnosis of localized PDAC and early interval CT scan (approx. 8 weeks). DNA was extracted with QIAamp DNA kits (Qiagen, Valencia, CA). Single locus, if tissue KRAS known, or multiplex (G12A, G12C, G12D, G12R, G12S, G12V, G13D) digital droplet PCR (ddPCR) was performed with QX200 (BioRad, Hercules, CA) ddPCR system. Disease status was determined by radiographic, CA19-9 and clinical evaluation. Results: N = 18 enrolled (median age: 65 [range 34-85]). Median time between baseline (B) and interval (I) blood was 2.53 months (range 0.9-6). One had locally recurrent disease, 2 AJCC stage IIa, 1 IIb and 14 III. Three had tissue KRAS G12D mutation, 6 G12V and 9 unknown. Eight had gemcitabine-based treatment, 10 5-FU-based and 5 radiation. See table. mKRAS and CA19-9 at B were not associated with progression free survival (PFS) or overall survival (OS). mKRAS detection at I was associated with shorter PFS/OS (P &lt; 0.01), but CA19-9 was not. mKRAS change from B to I was also associated with PFS/OS. For every 1 copy/mL increase in the change of mKRAS from B to I, the risk of death or progression/death increased by nearly 2 fold after controlling for baseline value (p = 0.01 for OS, p = 0.03 for PFS). Four patients, all undetectable mKRAS at I, went to surgery; 2/4 resected. Conclusions: In this pilot, 59% of localized PDAC patients had detectable mKRAS at B. mKRAS detection at I and change from B to I were associated with PFS/OS supporting that mKRAS early in treatment may be a useful prognostic and predictive marker in localized PDAC. We have initiated a large prospective trial to evaluate the predictive and prognostic potential of plasma mKRAS in advanced PDAC. [Table: see text]
TCT-358 Optical coherence tomography (OCT) guided percutaneous coronary intervention: clinical impact of acute abnormal findings after drug-eluting stent implantation detected only by OCT
Authors: Jae Young Cho, Cheol Woong Yu, Hyung Joon Joo, Jae Hyoung Park, Soon Jun Hong, Seung Hun Lee, Do-Sun Lim
Journal: Journal of the American College of Cardiology (2015)